Reintroduction of etanercept during treatment of cutaneous Mycobacterium marinum infection in a patient with ankylosing spondylitis.
Dare
Jason A
JA
University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, AR 72202-3591, USA. darejasona@uams.edu
Jahan
Shormi
S
Hiatt
Kim
K
Torralba
Karina D
KD
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D002175:Candida; D002179:Candidiasis, Cutaneous / Q000188:drug therapy; D017024:Chemotherapy, Adjuvant; D000068800:Etanercept; D006801:Humans; D016867:Immunocompromised Host; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007167:Immunotherapy; D008297:Male; D008875:Middle Aged; D009165:Mycobacterium Infections, Nontuberculous / Q000188:drug therapy*; D019910:Mycobacterium marinum; D009894:Opportunistic Infections / Q000188:drug therapy / Q000382:microbiology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D012867:Skin / Q000382:microbiology; D017192:Skin Diseases, Bacterial / Q000188:drug therapy*; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept